Add-on Anifrolumab for Residual Mucocutaneous and Systemic Manifestations During Cyclophosphamide Therapy in Severe Neuropsychiatric Lupus: A Case Report. (PubMed, Mod Rheumatol Case Rep) - Sep 30, 2026 - "Intravenous methylprednisolone pulse therapy and intravenous immunoglobulin were administered, but neurological improvement was limited, and intravenous cyclophosphamide therapy was initiated. Reports describing add-on anifrolumab during ongoing intravenous cyclophosphamide therapy for severe systemic lupus erythematosus are extremely limited. This case highlights the potential role of anifrolumab as an adjunctive therapy for persistent systemic and mucocutaneous manifestations suggestive of interferon-associated disease activity during ongoing cyclophosphamide-based intensive immunosuppressive treatment."
Journal • Alopecia • Immunology • Inflammatory Arthritis • Lupus • Pain • Psychiatry • Systemic Lupus Erythematosus
|
|
Jinhai Li; Koji Kinoshita; Mariko Hoshino; Shinya Rai; Toshihiko Shiga; Yuji Nozaki; Yumi Morimoto
|